Marshall Wace
ASND icon

Marshall Wace’s Ascendis Pharma A/S ASND Stock Holding History

Marshall Wace’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6M Buy
+22,503
New +$5.26M ﹤0.01% 1280
2026
Q1 		– Sell
-30,055
Closed -$6.41M – 3175
2025
Q4 		$6.41M Buy
30,055
+12,357
+70% +$2.55M 0.01% 1041
2025
Q3 		$3.52M Sell
17,698
-99,464
-85% -$18.6M ﹤0.01% 1350
2025
Q2 		$20.2M Buy
117,162
+94,868
+426% +$15.5M 0.02% 581
2025
Q1 		$3.47M Sell
22,294
-91,951
-80% -$13.1M ﹤0.01% 1221
2024
Q4 		$15.7M Sell
114,245
-106,830
-48% -$14M 0.02% 621
2024
Q3 		$33M Buy
221,075
+190,786
+630% +$25.8M 0.04% 370
2024
Q2 		$4.13M Buy
30,289
+5,205
+21% +$708K 0.01% 1083
2024
Q1 		$3.79M Buy
+25,084
New +$3.58M 0.01% 1108
2023
Q2 		– Sell
-108,326
Closed -$11.6M – 2450
2023
Q1 		$11.6M Buy
108,326
+4,900
+5% +$561K 0.02% 659
2022
Q4 		$12.6M Sell
103,426
-155,449
-60% -$18M 0.03% 693
2022
Q3 		$26.7M Buy
258,875
+192,159
+288% +$18.2M 0.06% 359
2022
Q2 		$6.2M Sell
66,716
-103,195
-61% -$9.73M 0.01% 1190
2022
Q1 		$19.9M Sell
169,911
-88,159
-34% -$10.2M 0.04% 499
2021
Q4 		$34.7M Buy
258,070
+244,605
+1,817% +$36.4M 0.06% 305
2021
Q3 		$2.15M Buy
+13,465
New +$1.84M 0.01% 1491
2020
Q2 		– Sell
-21,246
Closed -$2.39M – 1532
2020
Q1 		$2.39M Buy
21,246
+19,311
+998% +$2.51M 0.02% 572
2019
Q4 		$269K Sell
1,935
-802
-29% -$89.1K ﹤0.01% 1304
2019
Q3 		$263K Buy
+2,737
New +$305K ﹤0.01% 1236
2019
Q2 		– Sell
-28,948
Closed -$3.41M – 1338
2019
Q1 		$3.41M Buy
28,948
+10,921
+61% +$956K 0.03% 582
2018
Q4 		$1.13M Buy
18,027
+11,789
+189% +$741K 0.01% 881
2018
Q3 		$442K Sell
6,238
-5,520
-47% -$380K ﹤0.01% 952
2018
Q2 		$782K Sell
11,758
-460
-4% -$30.3K 0.01% 535
2018
Q1 		$799K Buy
+12,218
New +$687K 0.03% 285
2017
Q1 		– Sell
-87,558
Closed -$1.77M – 330
2016
Q4 		$1.77M Buy
+87,558
New +$1.75M 0.01% 665

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Marshall Wace's ASND Position: Q2 2026 in Review

Marshall Wace opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 22,503 shares worth $6M. The stake represents ﹤0.01% of the portfolio and ranks #1280 among its holdings. This is a return to the name: Marshall Wace previously reported a position in ASND as recently as Q4 2025.

Marshall Wace first reported a position in ASND in Q4 2016 and has held it in 25 quarters since. The position peaked at $34.7M in Q4 2021. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Marshall Wace held 22,503 shares of Ascendis Pharma A/S worth $6M as of Q2 2026.
  • Ascendis Pharma A/S was a new Marshall Wace position in Q2 2026.
  • Ascendis Pharma A/S made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1280 holding.
  • Marshall Wace first reported a position in Ascendis Pharma A/S in Q4 2016 and has held it in 25 quarters since.
  • Marshall Wace's Ascendis Pharma A/S position peaked at $34.7M in Q4 2021.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.